April 28, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt:2VP) is pleased to announce that it has hired local intellectual property law firm Oyen Wiggs Green & Mutala LLP to oversee the patenting of its new cannabis cultivars for specific disease conditions. This firm will also protect these new cultivars under the Plant Breeders’ Rights Act in Canada.

Veritas CEO, Lui Franciosi stated, “We’ve gotten great guidance thus far from their patent lawyer Thomas W. Bailey. Given the firm’s extensive experience in the area of plant protection as well as long history of success in BC, it made sense to hire them on permanent basis. They also got a great network of associates that will enable us to pursue protection in jurisdictions other than Canada and the United States.”

More information about Oyen Wiggs Green & Mutala LLP can be found at www.patentable.com

Please be advised that the Company will be issuing 500,000 stock options at $0.70 per share to its Directors, Officers and Consultants.

About VERITAS Pharma Inc.

Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share.

On behalf of the Board of Directors Veritas Pharma Inc.
“Dr. Lui Franciosi”
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact

Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: [email protected]
Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!